TRENDING :  Market Movers  |  Top 50   UHS (-8.2%)    UGAZ (-22.16%)    TVIX (7.92%)    TSLA (-2.95%)    SRPT (-2.05%)    SPY (-1.85%)    NBEV (0.85%)    MA (-1.83%)    HTGM (-1.97%)    GDX (-1.76%)    FB (-0.66%)    EWC (-1.17%)    CI (-3.11%)    CARA (-0.22%)    BTCUSD (%)    BHC (-3.3%)    ARGT (-1.53%)    AMZN (-4.01%)

 BIIB - Biogen Inc.

$314.55 (-1.75%)

Next Earnings



Analyst Rating

CompanyAnalyst NamePT ActionActionRatingTargetDate
JP MorganCory KasimovLowersMaintainsOverweight$436.0010/24/18
BernsteinDowngradesMarket Perform$0.0010/19/18
Cantor FitzgeraldAnnouncesReinstatesOverweight$400.0010/01/18
Stifel NicolausThomas ShraderAnnouncesReinstatesBuy$394.0008/07/18
UBSCarter GouldRaisesMaintainsBuy$395.0007/26/18
Morgan StanleyMatthew HarrisonRaisesMaintainsOverweight$392.0007/25/18
Canaccord GenuitySumant KulkarniRaisesMaintainsBuy$396.0007/23/18
Morgan StanleyMatthew HarrisonLowersMaintainsOverweight$366.0007/13/18
CitigroupRobyn KarnauskasAnnouncesUpgradesBuy$371.0007/06/18
Canaccord GenuitySumant KulkarniUpgradesBuy$0.0005/31/18
CitigroupRobyn KarnauskasLowersMaintainsNeutral$290.0005/02/18
BarclaysGeoff MeachamDowngradesEqual-Weight$0.0004/05/18
BMO CapitalIan SomaiyaLowersMaintainsOutperform$393.0003/05/18
MizuhoSalim SyedRaisesMaintainsBuy$433.0002/05/18
UBSCarter GouldUpgradesBuy$0.0001/31/18
H.C. WainwrightAndrew FeinRaisesMaintainsBuy$363.0001/26/18
Canaccord GenuitySumant KulkarniRaisesMaintainsHold$350.0001/24/18


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

For Immediate Release Chicago IL December 13 2018 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog

5 Pharma Stocks That Could Cure Ailing Portfolios in 2019

InvestorPlace Stock Market News Stock Advice amp Trading Tips The pharmaceutical sector delivers two benefits that appeal to investors reasonable P E ratios and growth catalysts Many pharma stocks have suffered as of late Some have key drugs facing patent expirations Meanwhile

Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

It was a pretty ho hum week for the biotech sector with regular pipeline and regulatory updates Key news include bigwig Gilead Sciences Inc GILD getting a new CEO and shares of Conatus Pharmaceuticals CNAT plummeting on the failure of lead candidate in the NASH study Recap of

Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for December 13, 2018

Gilead Sciences Inc GILD will begin trading ex dividend on December 13 2018 A cash dividend payment of 0 57 per share is scheduled to be paid on December 28 2018 Shareholders who purchased GILD prior to the ex dividend date are eligible for the cash dividend payment This marks the

The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

For Immediate Release Chicago IL December 12 2018 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog

4 Biotech Stocks Investors Can Add to Their Portfolio in 2019

It has been a disappointing year for the biotech industry The NASDAQ Biotechnology Index NBI has lost 5 so far in 2018 While the year started on a choppy note things were steady in the middle of the year However the industry lost momentum in the last two months The performance

iShares Nasdaq Biotechnology ETF Experiences Big Inflow

Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Nasdaq Biotechnology ETF Symbol IBB where we have detected an approximate 217 3 million dollar inflow that s a 2 7 increase week over week

Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis

Biogen Inc BIIB announced that it has obtained a worldwide license to develop and commercialize Ionis Pharmaceuticals IONS pipeline candidate BIIB067 IONIS SOD1RX This will enable the company to exercise an option per the deal it inked with Ionis in April 160 160 In April

FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101

Novartis AG NVS announced that the FDA has accepted the company s Biologics License Application BLA for AVXS 101 now known as Zolgensma onasemnogene abeparvovec xxxx The FDA also granted a Priority Review 160 to Zolgensma and regulatory action is expected in May 2019 Priority

AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018

AbbVie Inc ABBV presented encouraging long term follow up data from two clinical studies evaluating Venclexta venetoclax combo therapy and Imbruvica ibrutinib monotherapy at the annual meeting of the American Society of Hematology ASH The phase III MURANO study evaluated Venclexta

Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma

Teva Pharmaceutical Industries Ltd TEVA and its South Korean partner Celltrion announced that the FDA has approved their monoclonal antibody mAb biosimilar to Roche s RHHBY blockbuster cancer drug Rituxan rituximab The biosimilar will be available in the United States by the trade name

Why Is Biogen (BIIB) Up 4.5% Since Last Earnings Report?

A month has gone by since the last earnings report for Biogen BIIB Shares have added about 4 5 in that time frame outperforming the S amp P 500 Will the recent positive trend continue leading up to its next earnings release or is Biogen due for a pullback Before we dive into how

BIIB January 2019 Options Begin Trading

Investors in Biogen Inc Symbol BIIB saw new options begin trading today for the January 2019 expiration At Stock Options Channel our YieldBoost formula has looked up and down the BIIB options chain for the new January 2019 contracts and identified one put and one call contract of

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

If you re interested in broad exposure to the Healthcare Biotech segment of the equity market look no further than the Invesco Dynamic Biotechnology amp Genome ETF PBE a passively managed exchange traded fund launched on 06 23 2005 An increasingly popular option among retail

Validea's Top Five Healthcare Stocks Based On John Neff - 11/18/2018

The following are the top rated Healthcare stocks according to Validea s Low PE Investor model based on the published strategy of John Neff This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield The